3 patents currently held
16 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.
The next term ends in Nov 2039. from the record
Of the 16 now held by other companies, 15 name Regeneron Pharmaceuticals Inc. as their current owner, and 1 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Nov 2039
Next term end
3
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Nov 2041 · High confidence
Also notable
Ends Nov 2041 · Low confidence
Also notable
Ends Nov 2039 · High confidence
Compositions, Delivery Systems, and Methods Useful in Tumor Therapy
US 11,766,414
The most cited patent in this portfolio, cited by 8 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2041.
Compositions, Imaging, and Therapeutic Methods Targeting Folate Receptor 1 (FOLR1)
US 11,733,246
The newest of the three, granted 2023. It anchors the portfolio to 2041, later than anything else here. A terminal disclaimer caps this term to an earlier patent's.
Theranostic Capture Agents, Compositions, and Methods of Using and Making
US 11,638,764
The newest of the three, granted 2023. It anchors the portfolio to 2039, later than anything else here.
Formerly held, still cited
Notable
Ends Mar 2036 · High confidence
Cited by 18 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2036.
now held by Regeneron Pharmaceuticals, Inc.
Also notable
Ends Mar 2034 · High confidence
The most cited patent in this portfolio, cited by 21 later US patents, top 25% of utility patents granted in 2016 in our data. Protection runs to 2034.
now held by Regeneron Pharmaceuticals, Inc.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 22, 2027The maintenance fee for Compositions, Imaging, and Therapeutic Methods Targeting Folate Receptor 1 (FOLR1) (US 11,733,246) comes due Feb 22, 2027. Unpaid by Aug 23, 2027, it lapses early.
- 1 fee due Mar 26, 2027The maintenance fee for Compositions, Delivery Systems, and Methods Useful in Tumor Therapy (US 11,766,414) comes due Mar 26, 2027. Unpaid by Sep 27, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 2 largest of its 3 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Compositions, Imaging, and Therapeutic Methods Targeting Folate Receptor 1 (FOLR1) | 1 in force | to Nov 2041 |
| Compositions, Delivery Systems, and Methods Useful in Tumor Therapy | 1 in force | to Nov 2041 |
Patents held now
Soonest term end first.
Showing 1 to 3 of 3
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,638,764 | Theranostic Capture Agents, Compositions, and Methods of Using and Making In force · High confidence | In force | High confidence | |
| US 11,733,246 | Compositions, Imaging, and Therapeutic Methods Targeting Folate Receptor 1 (FOLR1) In force · Low confidence | In force | Low confidence | |
| US 11,766,414 | Compositions, Delivery Systems, and Methods Useful in Tumor Therapy In force · High confidence | In force | High confidence |
Also on record, not counted in the 3: 16 patents in force now held by others · 6 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.